reports
Cardiff Oncology to Participate in Two Upcoming Investor Conferences
Cardiff Oncology to Participate in Two Upcoming Investor Conferences SAN DIEGO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in two upcoming investor conferences in October 2025. Details of the events can be found below. Piper Sandler Virtual Oncology Symposium Format: Fireside Chat Presenters: Mark Erlander, PhD (CEO), James Levine (CFO), and Roger Sidhu, MD (CMO)Date: 10/09/2025Time:...
Verrica Pharmaceuticals Announces That Development Partner, Torii Phar...
Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH® (TO-208) in Japan for the Treatment of Molluscum Contagiosum – Approval triggers $10 million cash milestone payment to Verrica – – YCANTH® approval in Japan addresses significant unmet need of patients with molluscum – – Verrica maintains ownership of global rights to YCANTH for all indications in all territories outside of Japan – WEST CHESTER, Pa., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics co...
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Ann...
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference WEST CHESTER, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the H.C. Wainwright 27th Annual Global Investment Conference in New York City. H.C. Wainwright 27th Annual Global Investment Confer...
Cardiff Oncology to Participate in Three Upcoming Investor Conferences
Cardiff Oncology to Participate in Three Upcoming Investor Conferences SAN DIEGO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in the three upcoming investor conferences in September 2025. Details of the events can be found below. Wells Fargo 20th Annual Healthcare Conference Format: 1x1 Meetings Date: 09/05/2025Location: Encore Boston Harbor, Everett, MA Morgan Stanley 23rd Annual Gl...
Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results
Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results – Company reports $12.7 million in revenue in Q2’25, consisting primarily of $4.5 million in YCANTH® revenue, net, reflecting sequential growth of 32.5% over Q1’25 and $8.0 million in milestone revenue from Torii Pharmaceutical – – Completed Successful End of Phase 2 Meeting for VP-315 for Basal Cell Carcinoma; Company is preparing for the Phase 3 program and exploring non-dilutive opportunities for financing further development – – Conference call scheduled for today at 4:30 pm ET – WEST CHESTER, Pa., Aug. ...
Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Result...
Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025 WEST CHESTER, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Tuesday, August 12, 2025, to discuss the Company's financial results for the second quarter ending June 30, 2025, and provide a corporate update. In...
- Jonathan Moreland
MERC MERCER INTERNATIONAL INC.
CDXS CODEXIS
PETS PETMED EXPRESS INC.
CLRB CELLECTAR BIOSCIENCES
NHF NEXPOINT CREDIT STRATEGIES FUN
CZWI CITIZENS COMMUNITY BANCORP
LOOP LOOP INDUSTRIES
CHMG CHEMUNG FINANCIAL CORP.
FVCB FVCBANKCORP
FGBI FIRST GUARANTY BANCSHARES
GRX THE GABELLI HEALTHCARE & WELLNESSRX TRUST
CMTV COMMUNITY BANCORP INC. VT
DMAC DIAMEDICA THERAPEUTICS INC.
CRDF CARDIFF ONCOLOGY INC
IMRX IMMUNEERING CORP
NSPR INSPIREMD INC
BRCC BRC INC
LEXX LEXARIA BIOSCIENCE CORP
PMNT PERFECT MOMENT LTD.
DMA DESTRA MULTI ALTERNATIVE FUND
NYC NEW YORK CITY REIT
GF INC.
FGEN THE NEW GERMANY FUND
CCIF INC.
CVM FIBROGEN INC.
CARLYLE CREDIT INCOME FUND
CEL-SCI CORPORATION
- Jonathan Moreland
ANTM ANTHEM INC.
SSB SOUTH STATE CORPORATION
SNV SYNOVUS FINANCIAL CORP.
SIGI SELECTIVE INSURANCE GROUP INC.
SFNC SIMMONS FIRST NATIONAL CORPORATION CLASS A
RLI RLI CORP.
PSX PHILLIPS 66
PRGS PROGRESS SOFTWARE CORPORATION
PNFP PINNACLE FINANCIAL PARTNERS INC.
NVCR NOVOCURE LTD.
MTH MERITAGE HOMES CORPORATION
MSCI MSCI INC. CLASS A
MOFG MIDWESTONE FINANCIAL GROUP
FBIZ FIRST BUSINESS FINANCIAL SERVICES
CNC CENTENE CORPORATION
CHTR CHARTER COMMUNICATIONS INC. CLASS A
ALGN ALIGN TECHNOLOGY INC.
UPS UNITED PARCEL SERVICE INC. CLASS B
PETS PETMED EXPRESS INC.
EPD ENTERPRISE PRODUCTS PARTNERS L.P.
PBT PERMIAN BASIN ROYALTY TRUST
LIND LINDBLAD EXPEDITIONS HOLDINGS
KYN KAYNE ANDERSON MLP INVESTMENT CO.
PLBC PLUMAS BANCORP
CZWI CITIZENS COMMUNITY BANCORP
MBIN MERCHANTS BANCORP
PGC PEAPACK-GLADSTONE FINANCIAL CORP.
LOOP LOOP INDUSTRIES
CHMG CHEMUNG FINANCIAL CORP.
FVCB FVCBANKCORP
TLRY TILRAY
TROX TRONOX HOLDINGS PLC
AMTB AMERANT BANCORP (A)
PCB PACIFIC CITY FINANCIAL CORP
DMAC DIAMEDICA THERAPEUTICS INC.
CRDF CARDIFF ONCOLOGY INC
ABSI ABSCI CORP
NSPR INSPIREMD INC
BRCC BRC INC
JMSB JOHN MARSHALL BANCORP INC
PRME PRIME MEDICINE INC
MMC MARSH & MCLENNAN COMPANIES INC.
STRW STRAWBERRY FIELDS REIT INC.
AURX NUO THERAPEUTICS
DMA INC.
MRAI DESTRA MULTI ALTERNATIVE FUND
GF MARPAI
CVM INC.
THE NEW GERMANY FUND
INC.
CEL-SCI CORPORATION
- Jonathan Moreland
SHEN SHENANDOAH TELECOMMUNICATIONS COMPANY
PNFP PINNACLE FINANCIAL PARTNERS INC.
FFIN FIRST FINANCIAL BANKSHARES INC
CHTR CHARTER COMMUNICATIONS INC. CLASS A
CDXS CODEXIS
CIVB CIVISTA BANCSHARES
CZWI CITIZENS COMMUNITY BANCORP
MBIN MERCHANTS BANCORP
CCO CLEAR CHANNEL OUTDOOR HOLDINGS INC
CRDF CARDIFF ONCOLOGY INC
JMSB JOHN MARSHALL BANCORP INC
MMC MARSH & MCLENNAN COMPANIES INC.
Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase...
Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004) – Trial demonstrates 49% confirmed ORR in the 30mg onvansertib dose arm versus 30% confirmed ORR in the control arm in intent-to-treat population (N=110) – – Early PFS data show a trend favoring 30mg onvansertib dose arm vs. control arm – – Onvansertib continues to be well-tolerated and demonstrates a dose dependent response for all endpoints including ORR, early tumor shrinkage and depth of response – – Company will hold a conference call today at 4:30 p.m. ET ...
Cardiff Oncology Reports Second Quarter 2025 Results and Provides Busi...
Cardiff Oncology Reports Second Quarter 2025 Results and Provides Business Update - Appointed Dr. Roger Sidhu as Chief Medical Officer - - Completed enrollment in randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer (“mCRC”) - - Announced positive data from investigator-initiated trial of onvansertib in combination with paclitaxel in mTNBC at ASCO 2025 - - Cash and investments of $71.0 million as of June 30, 2025, projected runway into Q1 2027 - - Company to hold a conference call today at 4:...
Verrica Pharmaceuticals Reports Strong Growth in YCANTH® Dispensed App...
Verrica Pharmaceuticals Reports Strong Growth in YCANTH® Dispensed Applicator Units in 2Q 2025 – Company reports sequential quarterly growth of 32.8% over Q1 2025 with a record 13,434 YCANTH® dispensed applicator units in Q2 2025 – – Company reports receipt of $8 million milestone payment from its Japanese development partner, Torii Pharmaceutical, for initiation of global Phase 3 program in common warts – WEST CHESTER, Pa., July 09, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medica...
Verrica Pharmaceuticals Announces Amendment to Collaboration and Licen...
Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts – Verrica to receive a $8 million milestone payment for initiation of the global study in July 2025, ahead of previous schedule – – Verrica to receive a $10 million milestone payment from Torii in cash upon the approval of YCANTH® (TO-208 in Japan) for molluscum contagiosum in Japan; approval decision expected by the end of 2025 – – Torii to fund the first $40 million of out-of-pocket...
Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and...
Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC – Veteran executive with over 20 years of oncology leadership and clinical experience with proven track record of success in bringing development candidates through late-stage clinical development – – Company will hold a conference call on July 29 at 4:30 p.m. ET/1:30 p.m. PT to share additional clinical data from its randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-m...
REV Group Inc: 1 director
A director at REV Group Inc sold 92,601 shares at 43.830USD and the significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...
Cardiff Oncology Announces Positive Data from Investigator-Initiated T...
Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025 – Results from Phase 1b clinical trial evaluating onvansertib + paclitaxel for metastatic triple negative breast cancer demonstrated 40% objective response rate – – The trial evaluated three doses of onvansertib in combination with paclitaxel, and objective responses were observed only at the highest dose of onvansertib – – The combination was well-tolerated and demonstrated a safe and manageable toxici...
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthc...
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York WEST CHESTER, Pa., May 28, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the Jefferies Global Healthcare Conference in New York City. Jefferies Global Healthcare Conference, June 3-5, 2025Event details:Date:...
Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results
Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results – Company reports $3.4 million in YCANTH revenue, reflective of increasing demand, following the dispensing of more than 10,000 applicator units in the quarter, the most in company history and a 16.7% growth over Q4’24 – – Late-stage pipeline continues to advance with completion of end-of-Phase 2 meeting with Food and Drug Administration for VP-315, Verrica’s candidate for basal cell carcinoma, and continued advancement towards initiation of global Phase 3 program in common warts (VP-102/YCANTH) with partner Torii Pharmaceuti...
Cardiff Oncology Reports First Quarter 2025 Results and Provides Busin...
Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update - Completed enrollment in randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer (“mCRC”) - - Expanded intellectual property portfolio with second patent covering treatment of all bev-naïve patients, including RAS-mutated and RAS wild-type mCRC, across all lines of therapy - - Cash and investments of $79.9 million as of March 31, 2025, projected runway into Q1 2027 - SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Car...
Good Times Restaurants Inc: 1 director
A director at Good Times Restaurants Inc sold 11,331 shares at 2.000USD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.